Synthon announced today that it has successfully concluded multiple registration procedures for rosuvastatin 5mg, 10mg, 15mg, 20mg and 40mg film-coated immediate release tablets. Regulatory clearance for rosuvastatin has been obtained in 14 European countries.
Synthon's rosuvastatin is a cardiovascular product and a fully bioequivalent version of AstraZeneca’s Crestor®. Synthon’s 15 mg product is an additional dosage strength versus the Crestor® portfolio.
Annual European sales of Rosuvastatin are around EUR 1.1 billion. Synthon’s rosuvastatin is part of a rich pipeline of research projects and pending regulatory applications.
* Crestor® is a registered trademark of the AstraZeneca group of companies.
Synthon, with headquarters in Nijmegen, the Netherlands, is an international fast-growing pharmaceutical company and a leader in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of Multiple Sclerosis and Oncology. Synthon employs about 1,400 staff at 11 sites worldwide, and in 2010 it recorded a turnover of EUR 230 million. For more information, go to www.synthon.com.